Pharma Patent Position May Be Shakier; Supreme Court Seems To Favor IPR Standard
This article was originally published in The Tan Sheet
Executive Summary
Chief Justice Roberts criticizes broad interpretation of patent terms in inter partes reviews, but he seems in the minority.
You may also be interested in...
Permanent Vaccine Facility Should Be On Standby For Future Pandemics, Moncef Slaoui Says
Operation Warp Speed confirmed the necessity of having a facility on hand to develop and manufacture a vaccine for the next crisis, the outgoing advisor says.
FDA’s COVID-19 Pandemic Plan Calls For Ongoing Clinical Trial Innovation
Broader use of adaptive trial designs and master protocols, checklist-based application review, and enhancement of real-world monitoring of products are among the recommendations of US FDA's COVID-19 Pandemic Recovery and Preparedness Plan (PREPP) report, an effort months in making based on interviews with agency management, staff, and outside stakeholders.
US FDA To Lose Another COVID-19 Response Leader With Anand Shah’s Resignation
Shah, deputy commissioner for medical and scientific affairs, has been overseeing FDA’s COVID-19 Pandemic Recovery and Preparedness Plan. His departure the week of 20 January follows that of FDA Chief Counsel Amy Amin, whose resignation led to dueling appointments to temporarily fill her post.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: